Trial · NCT00939510
Adverse events18
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 18 of 18
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Lenalidomide (Revlimid) and Sargramostim (GM-CSF) | 15 | 31 | |
| other | Constipation | Gastrointestinal disorders | Lenalidomide (Revlimid) and Sargramostim (GM-CSF) | 10 | 31 | |
| other | Diarrhea | Gastrointestinal disorders | Lenalidomide (Revlimid) and Sargramostim (GM-CSF) | 9 | 31 | |
| other | Elevated Lactate dehydrogenase (LDH) | Investigations | Lenalidomide (Revlimid) and Sargramostim (GM-CSF) | 5 | 31 | |
| other | Fatigue | General disorders | Lenalidomide (Revlimid) and Sargramostim (GM-CSF) | 22 | 31 | |
| other | Hypocalcemia | Metabolism and nutrition disorders | Lenalidomide (Revlimid) and Sargramostim (GM-CSF) | 7 | 31 | |
| other | Injection site reactions | General disorders | Lenalidomide (Revlimid) and Sargramostim (GM-CSF) | 17 | 31 | |
| other | Leukopenia | Blood and lymphatic system disorders | Lenalidomide (Revlimid) and Sargramostim (GM-CSF) | 11 | 31 | |
| other | Lymphopenia | Investigations | Lenalidomide (Revlimid) and Sargramostim (GM-CSF) | 12 | 31 | |
| other | Nausea/Vomiting | Gastrointestinal disorders | Lenalidomide (Revlimid) and Sargramostim (GM-CSF) | 11 | 31 | |
| other | Neutropenia | Cardiac disorders | Lenalidomide (Revlimid) and Sargramostim (GM-CSF) | 12 | 31 | |
| other | Skin (dryness, rash, pruritus) | Skin and subcutaneous tissue disorders | Lenalidomide (Revlimid) and Sargramostim (GM-CSF) | 16 | 31 | |
| other | Taste Alterations | Nervous system disorders | Lenalidomide (Revlimid) and Sargramostim (GM-CSF) | 7 | 31 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Lenalidomide (Revlimid) and Sargramostim (GM-CSF) | 17 | 31 | |
| serious | Deep Venous Thrombosis (DVT)/Embolism | Cardiac disorders | Lenalidomide (Revlimid) and Sargramostim (GM-CSF) | 1 | 31 | |
| serious | Elevated Lactate dehydrogenase (LDH) | Investigations | Lenalidomide (Revlimid) and Sargramostim (GM-CSF) | 2 | 31 | |
| serious | Leukopenia | Blood and lymphatic system disorders | Lenalidomide (Revlimid) and Sargramostim (GM-CSF) | 1 | 31 | |
| serious | Neutropenia | Blood and lymphatic system disorders | Lenalidomide (Revlimid) and Sargramostim (GM-CSF) | 3 | 31 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00939510/events